At the time of writing, Tarsus Pharmaceuticals Inc [TARS] stock is trading at $70.14, down -0.34%. In order to assess the stock’s recent performance, you can check whether its short-term value is rising or falling. The TARS shares have gain 7.63% over the last week, with a monthly amount glided 35.22%, and seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
On November 20, 2023, Goldman initiated with a Neutral rating and assigned a price target of $19 on the stock. William Blair started tracking the stock assigning a Outperform rating and suggested a price target of $44 on July 18, 2023. Guggenheim initiated its recommendation with a Buy. Barclays started tracking with a Overweight rating for this stock on August 01, 2022, and assigned it a price target of $40. In a note dated December 21, 2021, H.C. Wainwright initiated a Buy rating and provided a target price of $40 on this stock.
For the past year, the stock price of Tarsus Pharmaceuticals Inc fluctuated between $33.95 and $70.78. Currently, Wall Street analysts expect the stock to reach $84 within the next 12 months. Tarsus Pharmaceuticals Inc [NASDAQ: TARS] shares were valued at $70.14 at the most recent close of the market. An investor can expect a potential return of 19.76% based on the average TARS price forecast.
Analyzing the TARS fundamentals
According to Tarsus Pharmaceuticals Inc [NASDAQ:TARS], the company’s sales were 295.52M for trailing twelve months, which represents an 151.54% jump. Gross Profit Margin for this corporation currently stands at 0.93% with Operating Profit Margin at -0.33%, Pretax Profit Margin comes in at -0.31%, and Net Profit Margin reading is -0.31%. To continue investigating profitability, this company’s Return on Assets is posted at -0.19, Equity is -0.32 and Total Capital is -0.24. Upon thorough examination of the company’s fundamental financial framework, it becomes apparent that the debt-to-equity ratio stands at 0.22.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance.
Ratios To Look Out For
It is important to note that Tarsus Pharmaceuticals Inc [NASDAQ:TARS] has a current ratio of 5.26. In addition, the Quick Ratio stands at 5.21 and the Cash Ratio stands at 1.07. Considering the valuation of this stock, the price to sales ratio is 10.02, the price to book ratio is 8.90.
Transactions by insiders
Recent insider trading involved Azamian Bobak R., President/CEO and Board Chair, that happened on Sep 24 ’25 when 6000.0 shares were sold. Officer, Bobak Azamian Living Trust completed a deal on Sep 24 ’25 to buy 6000.0 shares. Meanwhile, Director LINK WILLIAM J PHD sold 27116.0 shares on Sep 08 ’25.
